AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Oxis 9mcg Turbuhaler Clinical Experience Investigation
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2012-12-13
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 398
- Registration Number
- NCT01749462
- Locations
- 🇯🇵
Research Site, Yamanashi, D5127l00001, Japan
Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets
Phase 1
Completed
- Conditions
- Inhibition on Platelet Aggregation
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 258
- Registration Number
- NCT01744288
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Acid Suppressing Drug Seizure Epidemiology Study
Completed
- Conditions
- Seizure
- Interventions
- Drug: Risk of seizure
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8605
- Registration Number
- NCT01744301
- Locations
- 🇪🇸
Research Site, Madrid, Spain
A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Young VolunteersHealthy Elderly Volunteers
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-12-03
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 72
- Registration Number
- NCT01739647
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.
Phase 1
Completed
- Conditions
- Asthma,Pharmacokinetics,λz,MetaboliteCmax,Ketoconazole,AUC,Tmax,
- Interventions
- First Posted Date
- 2012-11-28
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT01735240
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2017-10-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 13885
- Registration Number
- NCT01732822
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Non-Insulin-DependentHigh Risk for Cardiovascular Event
- Interventions
- Drug: Placebo tablet
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2019-12-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17190
- Registration Number
- NCT01730534
- Locations
- 🇻🇳
Research Site, Ho Chi Minh City, Vietnam
Better Diabetes Control, Quality - Educate to Achieve Compliance.
Completed
- Conditions
- Diabetes Type 2
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 227
- Registration Number
- NCT01728714
- Locations
- 🇵🇹
Research Site, Santo Antonio Dos Cavaleiros, Portugal
Nexium Capsules LDA Specific Clinical Experience Investigation
Completed
- Conditions
- Gastric UlcerDuodenal Ulcer
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2363
- Registration Number
- NCT01729182
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 42
- Registration Number
- NCT01725230
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States